We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
Read MoreHide Full Article
The second-quarter reporting cycle seems to have gotten off to a good start, with an abundance of positive surprises, particularly on the revenue front. Meanwhile, earnings and revenue growth also bettered expectations.
As of Jul 21, 2017, 97 S&P 500 members, accounting for 28.1% of the index’s total market capitalization, reported results, according to Earnings Preview.
Total earnings for these 97 index members were up 8.4% from the year-ago quarter on a 5.1% improvement in revenues. The beat ratio was 78.4% for earnings and 72.2% for revenues.
The earnings momentum is expected to continue through the season. Per the report, total earnings for S&P 500 companies in the second quarter are expected to grow 8.6% year over year on 4.7% higher revenues. This follows 13.3% earnings growth in the first quarter on 7% increase in revenues, the highest in almost two years.
Among the pharma bigwigs, only Johnson & Johnson (JNJ - Free Report) and Swiss company Novartis AG (NVS - Free Report) have reported so far. J&J reported mixed second-quarter results, beating on earnings but missing on sales. This was the third consecutive sales miss for J&J due to a a slowdown in pharmaceutical product sales. However, J&J is optimistic that sales growth will accelerate in the second half of 2017. On the other hand, Novartis’ second-quarter results were encouraging as the company beat both earnings and sales estimates. However, Sandoz’s performance was disappointing due to pricing pressure.
Here we have three pharma giants that are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
Lilly, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 2.08% last quarter. Lilly’s earnings performance has been mixed with earnings missing expectations in two of the last four quarters and beating in the other two, resulting in an average negative surprise of 2.28%.
For this quarter, Lilly has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). The Zacks Consensus Estimate is pegged at $1.04 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
New products like Trulicity, Cyramza, Taltz and Jardiance have supported the top line in the past few quarters. We expect the trend to continue in the second quarter of 2017 as well. However, a decline in the sales of Alimta, Cymbalta and Zyprexa are expected to continue due to the loss of exclusivity. (Read More: Is a Beat in the Cards for Eli Lilly in Q2 Earnings?).
Our previous article showed that Lilly was likely to beat on earnings this quarter. However, estimates changed thereafter and we are not certain of a beat this earnings season.
Biogen, a well-known name in the multiple sclerosis (MS) market,is also scheduled to announce results before the opening bell. Biogen’s earnings performance has been pretty impressive so far, having delivered back-to-back positive surprises. The average earnings beat over the last four quarters is 5.29%.
Last quarter, the company delivered a positive earnings surprise of 4.63%.
Biogen expects relatively stable demand for both its key MS drugs, Tecfidera and Tysabri in 2017 as patient growth in ex-U.S. markets offset the modest decline in the U.S due to rising competition from drugs like Roche’s Ocrevus. (Read More: Can Biogen Keep the Earnings Streak Alive in Q2?)
The biotech giant is expected to report after market hours. Amgen delivered a positive earnings surprise of 5% in the last quarter. Amgen’s performance has been pretty impressive, with the company reporting positive surprises consistently. The average earnings beat over the last four quarters is 5.31%.
The company has an Earnings ESP of -0.32% and a Zacks Rank #3.
While Amgen’s growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth. (Read More: Amgen to Report Q2 Earnings: What's in the Cards?)
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
The second-quarter reporting cycle seems to have gotten off to a good start, with an abundance of positive surprises, particularly on the revenue front. Meanwhile, earnings and revenue growth also bettered expectations.
As of Jul 21, 2017, 97 S&P 500 members, accounting for 28.1% of the index’s total market capitalization, reported results, according to Earnings Preview.
Total earnings for these 97 index members were up 8.4% from the year-ago quarter on a 5.1% improvement in revenues. The beat ratio was 78.4% for earnings and 72.2% for revenues.
The earnings momentum is expected to continue through the season. Per the report, total earnings for S&P 500 companies in the second quarter are expected to grow 8.6% year over year on 4.7% higher revenues. This follows 13.3% earnings growth in the first quarter on 7% increase in revenues, the highest in almost two years.
Among the pharma bigwigs, only Johnson & Johnson (JNJ - Free Report) and Swiss company Novartis AG (NVS - Free Report) have reported so far. J&J reported mixed second-quarter results, beating on earnings but missing on sales. This was the third consecutive sales miss for J&J due to a a slowdown in pharmaceutical product sales. However, J&J is optimistic that sales growth will accelerate in the second half of 2017. On the other hand, Novartis’ second-quarter results were encouraging as the company beat both earnings and sales estimates. However, Sandoz’s performance was disappointing due to pricing pressure.
Here we have three pharma giants that are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
Eli Lilly and Company (LLY - Free Report)
Lilly, which is scheduled to release earnings before the market opens, had delivered a positive earnings surprise of 2.08% last quarter. Lilly’s earnings performance has been mixed with earnings missing expectations in two of the last four quarters and beating in the other two, resulting in an average negative surprise of 2.28%.
Eli Lilly and Company Price and EPS Surprise
Eli Lilly and Company Price and EPS Surprise | Eli Lilly and Company Quote
For this quarter, Lilly has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). The Zacks Consensus Estimate is pegged at $1.04 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
New products like Trulicity, Cyramza, Taltz and Jardiance have supported the top line in the past few quarters. We expect the trend to continue in the second quarter of 2017 as well. However, a decline in the sales of Alimta, Cymbalta and Zyprexa are expected to continue due to the loss of exclusivity. (Read More: Is a Beat in the Cards for Eli Lilly in Q2 Earnings?).
Our previous article showed that Lilly was likely to beat on earnings this quarter. However, estimates changed thereafter and we are not certain of a beat this earnings season.
Biogen Inc. (BIIB - Free Report)
Biogen, a well-known name in the multiple sclerosis (MS) market,is also scheduled to announce results before the opening bell. Biogen’s earnings performance has been pretty impressive so far, having delivered back-to-back positive surprises. The average earnings beat over the last four quarters is 5.29%.
Last quarter, the company delivered a positive earnings surprise of 4.63%.
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
The company has an Earnings ESP of -1.84% and a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen expects relatively stable demand for both its key MS drugs, Tecfidera and Tysabri in 2017 as patient growth in ex-U.S. markets offset the modest decline in the U.S due to rising competition from drugs like Roche’s Ocrevus. (Read More: Can Biogen Keep the Earnings Streak Alive in Q2?)
Amgen, Inc. (AMGN - Free Report)
The biotech giant is expected to report after market hours. Amgen delivered a positive earnings surprise of 5% in the last quarter. Amgen’s performance has been pretty impressive, with the company reporting positive surprises consistently. The average earnings beat over the last four quarters is 5.31%.
Amgen Inc. Price and EPS Surprise
Amgen Inc. Price and EPS Surprise | Amgen Inc. Quote
The company has an Earnings ESP of -0.32% and a Zacks Rank #3.
While Amgen’s growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth. (Read More: Amgen to Report Q2 Earnings: What's in the Cards?)
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>